David J. Straus, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the 3-year follow-up results of the ECHELON-1 study, which examines brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma.
David J. Straus, MD
Advertisement
Articles by David J. Straus, MD
David J. Straus, MD, internist and hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of pembrolizumab (Keytruda) as a treatment for patients with Hodgkin lymphoma.
David J. Straus, MD, an internist and hematologic oncologist at Memorial Sloan Kettering Cancer Center, discusses ongoing clinical trials in the field of Hodgkin lymphoma.
Advertisement
Latest Updated Articles
Dr. Straus on FDA Approval of Pembrolizumab in Hodgkin LymphomaPublished: March 15th 2017 | Updated:
Dr. Straus on Ongoing Clinical Trials in Hodgkin LymphomaPublished: February 15th 2017 | Updated:
Dr. Straus on the 3-Year Results of the ECHELON-1 Study in Hodgkin LymphomaPublished: July 31st 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes
4
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
5